Join this week’s webinar on #antibody-drug conjugates! Explore a full framework for ADC discovery and have your questions answered by industry experts. Register now: https://okt.to/GyBbcV
Discovery | Charles River
Biotechnology
Wilmington, MA 15,137 followers
Shouldn’t our next discovery be yours?
About us
Discovery from Charles River is industry-proven in the successful development of potential novel therapies, with over 100 preclinical drug candidates and over 420 patents delivered to our sponsors. Backed by more than 1,100 scientists, our comprehensive, multi-modality integrated portfolio employs the latest technology and platforms to provide chemistry, biology, pharmacology and toxicology services that support clients from the earliest stages of target discovery through IND. Our client-focused, collaborative approach creates true partnerships that anticipate challenges, overcome obstacles, and move us forward together on the journey of getting new drugs to market.
- Website
-
https://www.criver.com/products-services/discovery-services
External link for Discovery | Charles River
- Industry
- Biotechnology
- Company size
- 10,001+ employees
- Headquarters
- Wilmington, MA
Updates
-
Logica is the logical alliance fueling transformation in small molecule drug discovery, bringing together wet science experience with industry-leading #AI technology to add certainty and speed to your program. Dive deeper into the benefits of partnering with Logica by visiting our website. https://okt.to/z0eK8k #AI #Logica #Drugdiscovery #LogicaAI #SmallMolecule
-
Discovery | Charles River reposted this
🔵 Drug Discovery & Development | One Step through to Drug Product Development | Tech Transfer | Academic Research | Company Creation | Biotech
Great to be here at the #DMDG Open Meeting in #York. Stop by our stand, meet our team at the University of York today to learn more about our ADME/DMPK capabilities. Gary Wilson | Discovery & Development Joseph Zolnerciks, Ph.D. | Discovery & Development Claire Purdy | DMPK/ADME Senior Scientist Stuart Robjohns | DMPK Group Leader Discovery | Charles River #drugdevelopment #biotech #therapeutics #drugdiscovery #oncology #immunology #neuroscience #antibody #ophthalmology #cardiovascular #respiratory #inflammation #pharmaceuticals #chemistry #biology #CharlesRiver #Lifesciences #startups #ADME #DMPK
-
How does early #biomarker research benefit both patients and drug developers? Listen to this episode with biomarker expert Stefan Kostense to find out: https://okt.to/0W2xbg
-
How do you get hit identification right when the pressure is on to find hits that turn into advanceable candidates? Find out in this Q&A with Principal Scientific Advisor and research strategy expert Dr. Manu Kohli on critical pre-hit identification groundwork and decision-making: https://okt.to/Id8qXY
-
Are you considering options for integrating AI? Logica is your single partner with a shared purpose. Combining the trust and credibility of Charles River with the transformative AI capabilities of Valo Health, we enable success across every stage of your drug discovery journey. Reach out to explore how we can collaborate with you. https://okt.to/1vcEf4 #AI #Logica #Drugdiscovery #LogicaAI
-
Missed our webinar on AI in drug discovery? Watch the archive to learn how AI transforms R&D efficiency and success rates. Watch and listen as Dr. Thibault Géoui, Ph.D., MBA shares groundbreaking insights. Access the full webinar now! https://okt.to/EKkzuC #AI #drugdiscovery #biotech #Logica
-
Catch up on our recent webinar where we provide insights on how in silico, in vitro, and in vivo, PDX tools can optimize your preclinical phase, thanks to translationally relevant tumor biology models. https://okt.to/5f0nLD
AI, 3D, and Beyond: Harness the Power of New-generation Tools to Expedite PDX Efficacy Data
criver.com
-
Through our partnership with Cypre Inc. we offer #organoid model panels comprised of 42 3D tumors models of PDX-derived cell lines, human fibroblasts and PBMCs, which mimic the tumor microenvironment.
The Cypre 42 Panel - 3D Immuno-oncology models delivering predictive datasets for therapeutic efficacy and MOA in the tumor microenvironment. Learn more on our website: https://lnkd.in/g9caafvJ Cypre Inc. Charles River Laboratories
-
How do you get hit identification right when the pressure is on to find hits that turn into advanceable candidates? Find out in this Q&A with Principal Scientific Advisor and research strategy expert Dr. Manu Kohli on critical pre-hit identification groundwork and decision-making: https://okt.to/hgEKMI